Sovaldi (sofosbuvir) / Gilead - LARVOL DELTA

Comparing Care Settings for Sofosbuvir/ Ravidasvir Delivery in Hepatitis C: Nested Cohort Findings from the EASE Trial (APASL 2026) - No abstract available

Hepatitis C • Hepatology • Infectious Disease • Inflammation

Time to Viral Load Suppression with 8- versus 12-Week Ravidasvir/Sofosbuvir Regimens among Chronic Hepatitis C Patients in Malaysia (APASL 2026) - No abstract available

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates efficacy against HCV/HBV co-infection in vitro, and achieves HCV and HBV preclinical proof-of-concept, including equivalence to sofosbuvir (EASL 2026) - No abstract available

Preclinical • Hepatitis B • Hepatitis C • Infectious Disease

Substitutions M478K and A482G in the polymerase of yellow fever virus confer resistance to sofosbuvir and uprifosbuvir in vitro. (PubMed, Antiviral Res) - "A482G conferred slight cross-resistance to bemnifosbuvir, while no cross-resistance was observed for remdesivir, galidesivir, or NITD008...Sofosbuvir RAS described for other orthoflaviviruses did not substantially affect drug susceptibility in reverse-engineered YFV 17D. This study demonstrates that YFV can develop resistance to sofosbuvir and uprifosbuvir with only two NS5 substitutions that have slight impact on viral fitness."

Journal • Preclinical • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Inflammation • Liver Cancer • Solid Tumor • RAS

The effects of sofosbuvir on the colon of adult male albino rats and the potential protective role of propolis: A histological and immunohistochemical study. (PubMed, Tissue Cell) - "Propolis protected against colitis caused by sofosbuvir, regulating oxidation, inflammation, and cell proliferation."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Hepatitis C • Immunology • Infectious Disease • Inflammation • PCNA

Animal Models Illuminate Dengue Immunopathogenesis to Guide Vaccine and Therapeutic Developments. (PubMed, J Virol Methods) - "The protection provided by the monoclonal antibody C10 was shown to mitigate antibody-dependent enhancement (ADE) in murine models, though it is not associated with the Dengvaxia vaccine. The further development of these animal models will be necessary to expedite the safe development of next-generation dengue vaccines (TAK-003, TV003/TV005), antivirals (favipiravir, sofosbuvir), and immune modulators (IL-6 and TNF-α blockers) for use in endemic areas."

Journal • Preclinical • Review • Dengue Fever • Hematological Disorders • Infectious Disease • Obesity • IFNAR2 • IL1B • IL6

Investigating the time-dependent withdrawal effects of sofosbuvir and/or ribavirin on male mice: a histological and histophotometrical approach. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The administration of SFV and/or RBV for 5 days induced significant testicular injury, which was reversed after 175 treatments. Restorative effects underscore the potential safety of SFV/RBV regimens in human males."

Journal • Preclinical • Hepatitis C • Infectious Disease • Inflammation

A Decade Long, Real-life Experience of Sofosbuvir-based Regimen Use for Hepatitis C Treatment in People With End-stage Renal Disease. (PubMed, J Clin Exp Hepatol) - "They were treated with full-dose SOF (400 mg) in combination with either velpatasvir (VEL) 100 mg or daclatasvir (DAC) 60 mg. After achieving SVR12, eight and one patient had second and third episodes of HCV re-infections after 8 (4-13.5) months and 6 months, respectively, and five of them achieved SVR12 following retreatment. Sofosbuvir in combination with DAC or VEL are highly and equally effective against HCV in patients with eGFR below 30 mL/min."

Journal • Chronic Kidney Disease • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

A Prospective and Observational Study Evaluating the Efficacy and Safety of Coblopasvir in Combination with Sofosbuvir for the Treatment of Hepatitis C in the Northwest Region (ChiCTR) - P=N/A | N=150 | Completed | Sponsor: Tangdu Hospital of the Fourth Military Medical University; Tangdu Hospital of the Fourth Military Medical University

New trial • Hepatitis C • Infectious Disease • Inflammation

Bloodborne infections in dental practice: prevalence of markers and phylogenetic analysis of circulating strains. (PubMed, Vopr Virusol) - "The study reveals high viral hepatitis prevalence among dental patients. Detection of drug-resistant HCV variants and immune-evading HBV strains underscores the need for enhanced molecular surveillance, improved diagnostic protocols, and strengthened infection control measures."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Antiviral Drug Discovery from Typha angustifolia Pollen: Computational Analysis Targeting Flaviviridae Polymerases and Entry Proteins. (PubMed, Curr Pharm Des) - "Naringenin emerged as the most potent and reliable antiviral agent among the compounds of T. angustifolia, particularly against the RdRp of Japanese encephalitis. These computational insights validate T. angustifolia pollen as a promising natural antiviral resource, warranting further validation through in vitro and in vivo studies."

Journal • CNS Disorders • Dengue Fever • Hepatitis C • Infectious Disease • Inflammation

Mechanism of SARS-CoV-2 resistance to nucleotide analog-based antivirals. (PubMed, Nat Commun) - "Here, we reveal fundamental insights into how its unique proofreading exoribonuclease (ExoN) counteracts two representative NA antivirals, bemnifosbuvir and sofosbuvir, which are designed to inhibit the viral RNA polymerase (RdRp)...Furthermore, we identify an allosteric regulatory loop of ExoN that promotes the full activation of ExoN but is displaced by the binding of NAs exhibiting resilience to ExoN excision. These discoveries provide a molecular framework for understanding SARS-CoV-2 resistance to NA-based antivirals and highlight mechanisms that could be exploited to improve anti-coronavirus drug design."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Identification of NS5B resistance-associated mutations in hepatitis C virus circulating in treatment-naïve Cameroonian patients. (PubMed, IJID Reg) - "The clinically significant S282T mutation, which confers high-level resistance to sofosbuvir, was detected in one patient infected with HCV genotype 1e...Our investigation revealed that HCV patients who had not previously received DAA therapy exhibited a variety of NS5B gene alterations. Consequently, future treatment failure may be more likely due to these alterations."

Journal • Hepatitis C • Infectious Disease • Inflammation

Repurposing of FDA-Approved Antiviral Drugs Against Monkeypox Virus: Comparative In Vitro Screening and Structure Based In Silico Studies. (PubMed, Pharmaceuticals (Basel)) - "Twenty-three FDA-approved drugs, including Abacavir, Acyclovir, Amantadine, Chloroquine, Daclatasvir, Dolutegravir, Entecavir, Favipiravir, Hydroxychloroquine, Lamivudine, Molnupiravir, Nevirapine, Oseltamivir, Penciclovir, Remdesivir, Ribavirin, Sofosbuvir, Tenofovir, Valaciclovir, Valganciclovir, Velpatasvir, Zanamivir, and Zidovudine, were screened for potential anti-monkeypox activity in vitro...The employed computational methods indicate that remdesivir demonstrated superior binding patterns with elevated scores and stable complexes throughout the simulation. Our findings showed that Remdesivir therapeutic compound is potent against the tested strain of MPXV, and exhibited a robust binding affinity for Thymidylate Kinase, A42R Profilin-Like Protein, and VACV D13 enzymes, and thus may potentially be utilized as antiviral for the treatment of monkeypox virus."

FDA event • Journal • Preclinical • Infectious Disease

Cyclodextrin-based delivery of Annexin A1 mimetic Ac2-26 enhances anti-inflammatory effect and prevents dengue-induced lethality combined with antiviral therapy. (PubMed, Br J Pharmacol) - "These findings underscore the therapeutic potential of anti-inflammatory/pro-resolving strategies in severe dengue and support the development of CDX-Ac2-26 as a novel adjunctive treatment. Combining anti-inflammatory and antiviral approaches may enhance efficacy and reduce treatment-associated toxicity, offering a promising path for clinical translation."

Journal • Dengue Fever • Hematological Disorders • Infectious Disease • Inflammation • Thrombocytopenia • ANXA1 • CCL2

Reducing Small Molecule Adsorption in a PDMS-Based Microphysiological System of the Female Reproductive Tract via Parylene-C Coating to Improve Mechanistic Studies. (PubMed, ACS Appl Mater Interfaces) - "The beneficial effect of Parylene-C coating was most prominent for highly adsorbed drugs (lipophilic)─celicoxib and tamoxifen─while the low-adsorbed compounds (amphiphilic or hydrophilic) like aspirin, sofosbuvir, and perfluorooctanoic acid were unaffected. Importantly, by limiting molecular adsorption, we were able to demonstrate chemical effects in the FMi MPS device even when using highly PDMS-adsorbed compounds. Collectively, our results demonstrate an easily adoptable strategy to increase the toxicological utility of PDMS-made MPS devices by modifying surface properties and adsorption behavior through the use of a Parylene-C coating."

Journal

SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Center of target therapy

New trial • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Prodrug strategies in developing antiviral nucleoside analogs. (PubMed, RSC Med Chem) - "Antiviral nucleoside prodrugs have garnered considerable interest in drug discovery, leading to the approval of key drugs such as remdesivir (SARS-CoV-2), Sovaldi (hepatitis C virus, HCV), and tenofovir disoproxil fumarate [hepatitis B virus (HBV) and human immunodeficiency viruses (HIV)]. Their success lies in improving the oral bioavailability and delivering the parent drug to the targeted tissues. This review focuses on the prodrugs of antiviral nucleosides evaluated in humans (approved, in development or terminated), providing an overview of the different approaches utilized and discussing their in vitro and in vivo benefits."

Journal • Review • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

Impact of Direct Acting Antivirals on the hemodynamics of the portal circulation in cirrhotic patients infected with hepatitis C virus. (PubMed, Digestion) - "We infer that sustained virological response in HCV related cirrhotic patients following direct-acting antivirals may lead to decrease in portal hypertension after an extended period of time, as adopted from portal congestion index Doppler parameters."

Journal • Cardiovascular • Fibrosis • Gastroenterology • Hepatitis C • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Portal Hypertension • Solid Tumor • Thrombocytopenia

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023. (PubMed, J Viral Hepat) - "Viraemic patients were treated with 12- or 24-week regimens of sofosbuvir (400 mg) and daclatasvir (60 mg), depending on the fibrosis degree. The model appears feasible in terms of patient-level outcomes, though broader operational feasibility-including resources and scalability-was not formally assessed. Remaining barriers to treatment initiation and follow-up need to be addressed to advance national HCV elimination goals."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan (clinicaltrials.gov) - P=N/A | N=318 | Enrolling by invitation | Sponsor: Queen Mary University of London | Trial completion date: Sep 2025 ➔ Sep 2027 | Trial primary completion date: Sep 2025 ➔ Sep 2027

Trial completion date • Trial primary completion date • Hepatitis C • Infectious Disease • Inflammation

Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia (ISPOR-EU 2025) - "The EASE trial showed that an 8-week regimen of ravidasvir/sofosbuvir achieves over 90% sustained virological response, SVR12 and has over 97% adherence among vulnerable populations, proving non-inferior to the 12-week standard. This implementation science evaluation seeks to generate actionable evidence for enhancing Malaysia's hepatitis C elimination model and to provide innovative methodologies relevant to health system interventions in low- and middle-income countries. By yielding findings that inform evidence-based policy decisions, this study facilitates replication in similar contexts aiming for equitable hepatitis C elimination. The resulting framework effectively bridges the gap between policy, evidence, and frontline healthcare delivery, offering a sustainable model for other nations pursuing their HCV elimination goals."

Hepatitis C • Hepatology • Infectious Disease • Inflammation

SOFOSBUVIR BASED REGIMENS ARE EFFECTIVE FOR HEPATITIS C TREATMENT IN PATIENTS WITH END-STAGE RENAL DISEASE IN REAL-LIFE SETTING (AASLD 2025) - "Sofosbuvir in combination with daclatasvir or velpatasvir are highly and equally effective against HCV in CKD patients with eGFR below 30 mL/min."

Clinical • Chronic Kidney Disease • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

IN VITRO MODEL OF AURKB EXPRESSION LEVELS REGULATION MEDIATED BY SOFOSBUVIR TREATMENT (AASLD 2025) - " Cultures of Huh7 and Huh7.5 hepatoma cell lines were treated with SOF (C22H29N3FO9P) or daclatasvir (DCV) (BMS-790052) at different doses...All SOF-induced effects were reversed in the presence of AZD1152, an inhibitor of AURKB activity, confirming that they were exerted through the AURKB pathway... These results suggest that SOF can induce cell cycle modifications through AURKB activation in in vitro cell models. The effect of these changes in vivo (hepatitis C patients treated with SOF) should be analysed, taking into account that HCV eradication may induce an increase in AURKB per se, due to the inhibitory effect that the viral core protein exerts on AURKB activity."

Preclinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Solid Tumor • AURKB • DUSP1 • EGFR • PDGFRB

SOFOSBUVIR-BASED REGIMEN ACHIEVED HIGH VIROLOGICAL RESPONSE IN NON-GENOTYPED HCV PATIENTS FROM A GENOTYPE 3 HIGH-PREVALENCE REGION OF SOUTHWEST CHINA: A RETROSPECTIVE COHORT STUDY (SAIN-C) (AASLD 2025) - "Patients were treated with Sofosbuvir/Velpatasvir (SOF/VEL) or Ledipasvir/Sofosbuvir (LDV/SOF) ± Ribavirin(RBV) for 12 weeks. SOF-based regimen could achieve high SVR regardless of genotype testing, even in high-prevalence regions of HCV GT3 infection. We believe this simplified strategy could be considered for genotype testing unavailable areas."

Retrospective data • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation